• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Rubicon Organics Announces Appointment of Glen Ibbott as CFO

    11/12/25 8:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email

    VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary.

    "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impact as we scale operations and strengthen our position as Canada's leader in premium cannabis. We are thrilled to welcome Glen on board as a permanent member of our executive team and look forward to his continued contributions as we drive growth and innovation", said Margaret Brodie, CEO.

    Mr. Ibbott commented "I'm thrilled to continue my journey with Rubicon Organics as Chief Financial Officer. Over the past six months, I've seen firsthand the strength of our team, the power of our premium brands, and the incredible opportunities ahead as we scale and expand into new markets. Rubicon is uniquely positioned to lead the next chapter of growth in the high-quality, premium cannabis industry, and I'm excited to help unlock that potential and deliver long-term value for our shareholders."

    Glen Ibbott is a seasoned financial executive with over 25 years of leadership experience in publicly-traded life sciences and cannabis companies. He is best known in the industry for his tenure as CFO at Aurora Cannabis from 2017 to 2024, where he played a pivotal role in the company's rapid growth, international expansion, and delivery of recurring EBITDA and cash flow. Prior to Aurora, Mr. Ibbott held senior finance roles at several prominent healthcare and pharmaceutical companies, including QLT Inc., where he was instrumental in its $500 million merger with Aegerion Pharmaceuticals. He began his career at KPMG and holds the CPA designation in Canada, as well as MBAs from Cornell University and Queen's University. His strategic acumen and deep industry knowledge make him a valuable asset in guiding companies through complex financial landscapes. Glen has been working as an interim CFO with Rubicon over the past six months.

    ABOUT RUBICON ORGANICS INC.

    Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organics, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

    The Company's production base is anchored by its Pacifica facility (Delta, BC) and is now complemented by the acquisition and licensing of its Cascadia facility (Hope, BC), which will expand production capacity by over 40% and support future growth in both domestic and export markets. With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment.

    As the Canadian market continues to rationalize and global demand for high-quality cannabis increases, Rubicon Organics' disciplined execution, brand equity, and consumer loyalty set it apart. The Company's focus on premium quality, innovation, and operational execution has driven consistent revenue growth and positive Adjusted EBITDA.

    Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential.

    CONTACT INFORMATION

    Margaret Brodie

    CEO

    Phone: +1 (437) 929-1964

    Email: [email protected]

    The TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

    Cautionary Statement Regarding Forward Looking Information

    This press release contains "forward-looking information" within the meaning of applicable securities laws, including, but not limited to, statements regarding the Company's future growth, operational plans, market expansion, production capacity, financial performance, and strategic initiatives. Forward-looking information is based on management's current expectations and assumptions, which are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements.

    Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, assumptions regarding the Company's ability to execute its business strategy, maintain regulatory compliance, achieve production targets, expand into new markets, and realize anticipated benefits from recent appointments and facility expansions. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business, and political conditions; regulatory changes; competitive pressures; operational challenges; and other factors described in the Company's public filings available on SEDAR+ at www.sedarplus.ca.

    Readers are cautioned not to place undue reliance on such forward-looking information. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information.

    All forward-looking information in this press release is made as of the date hereof and is based on the beliefs, estimates, and opinions of management as of the date such statements are made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable law.



    Primary Logo

    Get the next $ACB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    10/5/2021$8.30 → $9.50Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    11/5/25 7:25:30 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    11/5/25 7:16:32 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    10/22/25 6:02:08 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rubicon Organics Announces Appointment of Glen Ibbott as CFO

    VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary. "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impac

    11/12/25 8:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

    Expands YoY Global Medical Cannabis Net Revenue1 by 15% to Record $70.5 millionIncreases International Medical Cannabis Net Revenue1 by 22% to Record $42.7 million, with leadership positions across key marketsDelivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.

    11/5/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Oct. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on Wednesday, November 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, November 5, 2025 TIME: 8:00 a.m. Easte

    10/22/25 5:15:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/23 11:28:04 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Aurora Cannabis Inc.

    SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

    6/1/22 10:14:29 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/22 3:54:29 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    View All

    Rubicon Organics Announces Appointment of Glen Ibbott as CFO

    VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary. "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impac

    11/12/25 8:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Inc. Announces Results of 2025 Annual General and Special Meeting

    NASDAQ | TSX: ACB EDMONTON, AB, Aug. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 8, 2025 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 17,736,521 common shares, representing 31.53% of Aurora's issued and outstanding common shares as of the record date.

    8/8/25 5:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

    VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics" or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. "Glen's leadership at Aurora C

    5/15/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Financials

    Live finance-specific insights

    View All

    Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

    Expands YoY Global Medical Cannabis Net Revenue1 by 15% to Record $70.5 millionIncreases International Medical Cannabis Net Revenue1 by 22% to Record $42.7 million, with leadership positions across key marketsDelivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.

    11/5/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis to Host Second Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Oct. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its second quarter 2026 on Wednesday, November 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the second quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, November 5, 2025 TIME: 8:00 a.m. Easte

    10/22/25 5:15:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora to Participate in Canaccord Genuity 45th Annual Growth Conference

    Canada's Largest Medical Cannabis Company to Discuss Strategy, Industry Trends, and Long-Term Growth Outlook EDMONTON, ALBERTA, Aug. 7, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, will participate in Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat on August 13th at 1:30pm EST and conduct one-on-one meetings with investors throughout the day. The discussion will cover Aurora's strategic direction, recen

    8/7/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Aurora Cannabis

    TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

    12/11/24 10:35:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

    2/9/24 6:09:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Aurora Cannabis from Sell to Hold

    9/21/22 9:02:55 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care